Bioniz Therapeutics, Inc. — Form D/A
Bioniz Therapeutics, Inc. of IRVINE, CA, a company, filed a Form D amendment with the SEC on 2017-04-13. The offering totals $18.6M, of which $15.6M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2017-04-13
- Form: D/A
- Accession: 0001662388-17-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $18.6M
- Amount sold: $15.6M
- Remaining: $3.1M
- Investors: 15
- Date of first sale: 2015-12-17
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-254158
Issuer
- Name: Bioniz Therapeutics, Inc.
- CIK: 0001662388
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2015
- Address: 5 MASON, IRVINE, CA, 92618
- Phone: 949-273-6000
Officers, directors & promoters (11)
| Name | Role | Location |
|---|
| David Pyott | Director | San Jose, CA |
| Ilan Zipkin | Director | OAKLAND, CA |
| Graham EI Cooper | Director | Irvine, CA |
| Paul EI Frohna | Executive Officer | Irvine, CA |
| Michael EI Martin | Director | Irvine, CA |
| Nazli Azimi | Director | Irvine, CA |
| Nazli Azimi | Executive Officer | Irvine, CA |
| David EI Pyott | Director | Irvine, CA |
| Joe Kiani | Director | Irvine, CA |
| Fredrik EI Wiklund | Executive Officer | Irvine, CA |
| Kleanthis Xanthopoulos | Director | Carlsbad, CA |
Other filings by this issuer (5)
More